Clinical application value of metagenome next-generation sequencing in pulmonary diffuse exudative lesions: a retrospective study

This study aims to investigate the clinical application value of Metagenome Next-Generation Sequencing (mNGS) for pulmonary diffuse exudative lesions. From January 1, 2014, to November 31, 2021, 136 cases with chest radiologic presentations of pulmonary diffuse exudative lesions admitted to Fujian P...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cellular and infection microbiology 2024-05, Vol.14, p.1367885-1367885
Main Authors: Wu, Yisong, Wu, Jian, Xu, Nengluan, Lin, Ming, Yue, Wenxiang, Chen, Yusheng, Zhang, Qiongyao, Li, Hongru
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Cellular and Infection Microbiology
diagnostic value
Female
High-Throughput Nucleotide Sequencing - methods
Humans
Lung - microbiology
Lung - pathology
Lung Diseases - diagnosis
Lung Diseases - microbiology
Male
Metagenome
metagenomic next-generation sequencing
Metagenomics - methods
Middle Aged
prognostic value
pulmonary diffuse exudative lesions
respiratory pathogens
Retrospective Studies
Sensitivity and Specificity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to investigate the clinical application value of Metagenome Next-Generation Sequencing (mNGS) for pulmonary diffuse exudative lesions. From January 1, 2014, to November 31, 2021, 136 cases with chest radiologic presentations of pulmonary diffuse exudative lesions admitted to Fujian Provincial Hospital were included in the study; of those, 77 patients underwent mNGS pathogen detection. Based on the pathogen detection outcomes and clinical diagnoses, patients were categorized into an infection group (IG) and a non-infection group (NIG). A comparison was made between the diagnostic efficacy of the mNGS technique and traditional culture methods. Meanwhile, 59 patients clinically identified as having infectious pulmonary diffuse exudative lesions but who did not receive mNGS testing were designated as the non-NGS infection group (non-IG). A retrospective cohort study was conducted on patients in both the IG and non-IG, with a 30-day all-cause mortality endpoint used for follow-up. When compared to conventional culture methods, mNGS demonstrated an approximate 35% increase in sensitivity (80.0% vs 45.5%, P
ISSN:2235-2988
2235-2988
DOI:10.3389/fcimb.2024.1367885